How Antibody Drug Technology Evolved Into a $267 Billion Medical Powerhouse

Therapeutic monoclonal antibodies (mAbs) now anchor treatment in oncology, immunology, hematology, neurology and infectious disease. They are also a commercial giant, with global sales exceeding USD 267 billion in 2024. Top sellers such as pembrolizumab (Keytruda), dupilumab (Dupixent) and adalimumab (Humira) show how much immuno-oncology and anti-inflammatory biologics dominate the pharmaceutical landscape. This review from Academia Sinica (Taiwan) updates the technologies behind that growth.

This is a narrative review, not a primary study. The authors trace the field from the introduction of hybridoma technology in 1975 through a series of platform innovations: chimeric and humanized antibody engineering, phage display, transgenic mouse platforms (e.g., XenoMouse, HuMab Mouse) and high-throughput single B cell isolation. They use a timeline figure and a table of FDA-approved antibodies to show how targets, formats, discovery technologies and indications have changed. Early approvals such as abciximab (1994) and rituximab (1997) came from hybridoma-derived chimeric molecules. Later fully human antibodies came from phage display (adalimumab, 2002) and transgenic mice (panitumumab, 2006; ustekinumab, golimumab and others in 2009).

As of August 2025, the authors cite GlobalData figures of 1,516 therapeutic antibody products in clinical development worldwide, excluding biosimilars and combination therapies. Sixteen have pre-registration status, 207 are marketed globally, and 144 are FDA-approved and on the market. The review describes engineering advances that moved the field beyond conventional mAbs into antibody-drug conjugates (ADCs), bispecific antibodies (bsAbs) and CAR-T cell therapies. Each of these has applications across multiple disease areas.

The authors highlight newer delivery and design strategies. mRNA-lipid nanoparticles and antibody-directed in vivo CAR-T cell reprogramming may allow precision therapy with fewer off-target effects and simpler manufacturing than conventional ex vivo cell therapy. AI and machine learning, next-generation sequencing and structural modeling are speeding up antibody discovery, affinity maturation and immunogenicity prediction, making design more rational and efficient. The review also covers clinical translation, regulatory landscapes and the integration of engineering, biology and informatics.

For readers, the main message is that antibody technology is maturing into a multidisciplinary, increasingly computational field. It may address unmet needs in cancer, autoimmune disease and neurological disease, with age-related conditions likely among the beneficiaries. Caveats: as a broad review it does not offer new clinical data or systematic comparisons of efficacy or safety. Market and pipeline figures come from a commercial database. Emerging approaches such as in vivo CAR-T and AI-designed antibodies are early-stage, and their clinical benefit and long-term safety remain unproven. The text supplied for this analysis was truncated, so this summary draws mainly on the abstract, introduction and the opening of the approvals table.